Over the last 2 years the lives of millions have changed because of the emergence of Coronavirus disease 2019 (COVID-19). Patients living with inflammatory bowel disease (IBD) represent a sizable population with their own sets of challenges to providers in the wake of so much uncertainty. The Centers for Disease Control considers immunocompromised individuals at higher risk of infection and complications from COVID-19. Early in the pandemic, the specific risks for IBD patients were unclear as guidance was based on expert opinion regarding the management of IBD during a COVID-19 era. Fortunately, after considerable work in the field, the overwhelming evidence suggests that IBD patients as a whole do not appear to be at increased risk for more severe disease from COVID-19. Certain risk factors such as age, steroids, comorbidities, combination immunomodulatory therapy, and IBD disease activity have been associated with worse outcomes. Most IBD medications are low risk, with the exception of immunomodulator monotherapy and combination therapy with thiopurine and anti-TNF. Vaccination remains safe and effective for all IBD patients, although additional booster doses may be necessary, particularly in patients taking anti-TNF agents.

中文翻译：

---

在 COVID-19 时代管理 IBD。

过去两年，由于 2019 年冠状病毒病 (COVID-19) 的出现，数百万人的生活发生了变化。炎症性肠病 (IBD) 患者人数众多，由于存在如此多的不确定性，他们也给医疗服务提供者带来了一系列挑战。疾病控制中心认为免疫功能低下的个体感染 COVID-19 和并发症的风险较高。在大流行早期，IBD 患者的具体风险尚不清楚，因为指导是基于关于 COVID-19 时代 IBD 管理的专家意见。幸运的是，经过该领域的大量工作，压倒性的证据表明，IBD 患者作为一个整体，似乎并没有因 COVID-19 而面临更严重疾病的风险增加。某些危险因素，如年龄、类固醇、合并症、联合免疫调节治疗和 IBD 疾病活动性与较差的结果相关。大多数 IBD 药物风险较低，但免疫调节剂单一疗法以及硫嘌呤和抗 TNF 联合疗法除外。尽管可能需要额外的加强剂量，特别是对于服用抗 TNF 药物的患者，但疫苗接种对于所有 IBD 患者仍然是安全有效的。